Inhibiting ER‐to‐Golgi transport could promote Golgi‐bypass routes of secretion – pathways increasingly recognized in cancer for releasing cytokines, enzymes, and glycoproteins that modulate the tumor microenvironment and promote metastasis.[32] Thus, TBC1D22B may enable the selective release of pro‐tumorigenic factors via non‐canonical routes, reshaping the secretome in ways that benefit tumor progression. Here, TBC1D22B is linked to cancer.